Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manesh R Patel

Showing results (461-470 of 596) with videos related to

Pageof 60
Sort By:
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
The American Journal of Cardiology|April 27, 2012
Cardiologist concordance with the American College of Cardiology appropriate use criteria for cardiac testing in patients with coronary artery diseaseFay Y Lin, Lisa R Rosenbaum, Dan Gebow, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2020
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID TrialAjar Kochar, Hillary Mulder, Frank W Rockhold, et al.
JAMA|November 17, 2014
Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarctionDuk-Woo Park, Robert M Clare, Phillip J Schulte, et al.
American Heart Journal|September 20, 2015
Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts studyGianluca Pontone, Manesh R Patel, Mark A Hlatky, et al.
The American Journal of Cardiology|July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
JACC. Cardiovascular Interventions|January 7, 2022
1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI: DEFINE PCI TrialManesh R Patel, Allen Jeremias, Akiko Maehara, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 60

Showing results (461-470 of 596) with videos related to

Sort By:
Pageof 60
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
The American Journal of Cardiology|April 27, 2012
Cardiologist concordance with the American College of Cardiology appropriate use criteria for cardiac testing in patients with coronary artery diseaseFay Y Lin, Lisa R Rosenbaum, Dan Gebow, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2020
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID TrialAjar Kochar, Hillary Mulder, Frank W Rockhold, et al.
JAMA|November 17, 2014
Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarctionDuk-Woo Park, Robert M Clare, Phillip J Schulte, et al.
American Heart Journal|September 20, 2015
Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts studyGianluca Pontone, Manesh R Patel, Mark A Hlatky, et al.
The American Journal of Cardiology|July 14, 2022
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)Rubina Attar, Angie Wu, Daniel Wojdyla, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
JACC. Cardiovascular Interventions|January 7, 2022
1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI: DEFINE PCI TrialManesh R Patel, Allen Jeremias, Akiko Maehara, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 60